Legend Biotech Corporation (Legend Biotech) announced that the U.S. Food and Drug Administration (FDA) has approved its first product, CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), to treat adult patients with relapsed or refractory multiple myeloma (RRMM) who have received four or more prior lines of therapy, including a proteasome inhibitor and an anti-CD38 monoclonal antibody. Multiple myeloma is an incurable cancer affecting plasma cells – a type of white blood cell found in the bone marrow. Patients with multiple myeloma who have been heavily pretreated face poor prognoses with limited treatment options, but CARVYKTI™ has the potential to become an impactful therapy option for patients. CARVYKTI™ is a genetically modified autologous T-cell immunotherapy that is B-cell maturation antigen (BCMA)-directed. The therapy involves reprogramming a patient’s own T-cells with a transgene encoding a chimeric antigen receptor (CAR) that identifies and eliminates cells expressing BCMA. Legend Biotech is a global biotechnology company that develops, manufactures, and commercializes novel cellular therapies to treat life-threatening diseases.
Read more here.